Consensus Tempus AI, Inc.

Stocks

TEM

US88023B1035

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 20:54:21 09/07/2026 +04			5-day change	1st Jan Change
60.98 ^USD	+6.49%		+0.53%	+2.61%

06-25	Tempus AI, Inc. and Angiosarcoma Awareness, Inc. Announce Research Collaboration to Uncover Insights on Rare Cancers	CI
06-11	Tempus AI Announces Multi-Center Validation Of AI-Enabled ECG Model For Predicting Atrial Fibrillation Risk	CI

Evolution of the Average Target: Tempus AI, Inc.

Evolution of the Target Price: Tempus AI, Inc.

Changes in Analyst Recommendations: Tempus AI, Inc.

6f3ae4a4a.KEVvb6MZV3jpPRlRnYpo2Aa9s34yOXZpZygz_UHY9Ns.W3JdO45pHS-7f1QQ07gk7mzP1i55VkQEPkdrsQnuspZkEzcVm0xlDrhQfg~64e71b1daa3fc68bce0d669f5b0d39d3

Analysts' recommendations: Tempus AI, Inc.

04-13	TD Cowen Upgrades Tempus AI to Buy From Hold, Adjusts Price Target to $65 From $70	MT
04-13	Jefferies Initiates Tempus AI at Underperform With $35 Price Target	MT
02-25	Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead…
02-19	Mizuho Securities Initiates Coverage on Tempus AI With Outperform Rating, $100 Price Target	MT
02-17	Baird Initiates Tempus AI at Outperform With $59 Price Target	MT
12-02	Morgan Stanley Raises Price Target on Tempus AI to $85 From $80, Keeps Overweight Rating	MT
11-11	Analyst recommendations: Coreweave, Duolingo, Lyft, Qualcomm, Tempus…
22/10/25	Analyst recommendations: 3M Company, Gartner, Halliburton, GM, Warner Bros Discovery…
21/10/25	Tempus AI Shares Lower After TD Cowen Downgrade	MT
21/10/25	TD Cowen Downgrades Tempus AI to Hold From Buy, Adjusts Price Target to $88 From $72	MT
20/10/25	Canaccord Genuity Initiates Coverage on Tempus AI With Buy Rating, $110 Price Target	MT
02/09/25	HC Wainwright Initiates Tempus AI at Buy With $90 Price Target	MT
06/08/25	Healthcare firm Personalis' Q2 revenue misses estimates	RE
21/04/25	BTIG Initiates Tempus AI at Buy With $60 Price Target	MT
26/02/25	Wolfe Research Downgrades Tempus AI to Peer Perform From Outperform	MT
25/02/25	Tempus AI Shares Fall After Downgrade from JPMorgan	MT
25/02/25	JPMorgan Downgrades Tempus AI to Neutral From Overweight, Adjusts Price Target to $55 From $50	MT
12/02/25	William Blair Downgrades Tempus AI to Market Perform From Outperform	MT
07/01/25	President Capital Initiates Tempus AI at Buy With $52 Price Target	MT
13/12/24	Wolfe Initiates Tempus AI at Outperform With $60 Price Target	MT
09/12/24	Guggenheim Initiates Tempus AI at Buy With $74 Price Target	MT
11/11/24	Stifel Nicolaus Downgrades Tempus AI to Hold From Buy, Adjusts Price Target to $65 From $45	MT
02/10/24	BofA Securities Downgrades Tempus AI to Neutral From Buy on Valuation Price Target Raised to $60 From $45	MT
12/08/24	Piper Sandler Initiates Tempus AI at Neutral With $40 Price Target	MT
09/07/24	Tempus AI Poised for 27% Topline Growth Through 2028, Morgan Stanley Says	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TEMPUS AI, INC.					+15.35%
	LONZA GROUP AG					+16.79%
	REVOLUTION MEDICINES, INC.					+4.81%
	IQVIA HOLDINGS INC.					+12.68%
	BEONE MEDICINES AG					+36.83%
	CELLTRION, INC.					+44.87%
	ASCENDIS PHARMA A/S					+6.02%
	MEDPACE HOLDINGS, INC.					-15.15%
	IONIS PHARMACEUTICALS, INC.					+24.16%
	EUROFINS SCIENTIFIC SE					+5.92%
	Average					+15.23%
	Weighted average by Cap.					+17.09%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

57.27USD

Average target price

66.06USD

Spread / Average Target

+15.35%

High Price Target

100.00USD

Spread / Highest target

+74.61%

Low Price Target

35.00USD

Spread / Lowest Target

-38.89%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Jefferies & Co.
TD Cowen
Mizuho Securities
Baird
Morgan Stanley
Canaccord Genuity
HC Wainwright
BTIG
Wolfe Research
JPMorgan Chase
William Blair & Co.
President Capital Management
Guggenheim
Stifel Nicolaus
BofA Securities